Turn £10k Into £18.5k With GlaxoSmithKline plc

Even during a troubled decade, GlaxoSmithKline plc (LON: GSK) shares have performed reasonably.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskI took a look recently at AstraZeneca, and was impressed to see an overall trebling in value over the past 10 years if all dividends were reinvested.

The FTSE 100‘s other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn’t been doing quite so well — for one thing, it hasn’t had its shares boosted by takeover fever.

A 20% gain?

If you’d invested £10,000 in GlaxoSmithKline shares 10 years ago, you’d have been paying around 1,191p apiece — and at that price you could have bagged 839 shares (ignoring dealing costs).

Now, the share price has only gained 21.5% over the period, and your ten grand would have grown to £12,149. While that might have matched cash in a savings account, we really expect better from investing in shares.

But that doesn’t include dividends, so what would those have added?

Rising dividends

GlaxoSmithKline has actually been paying pretty decent dividends, starting the period offering yields of around 3.5%. But that started ramping up in 2007 as the share price fell a little, reaching 5% by 2009 — and yields have remained close to that level since. 

One thing that does mean is that dividends alone would have easily been enough to beat cash sitting in the bank, without any share price gain!

Earnings per share (EPS) can be a little volatile, but even when EPS didn’t cover the dividend in 2010, Glaxo maintained the cash payment from its own resources — and EPS was back up to normal the next year.

Another five grand!

In total, GlaxoSmithKline would have paid you an extra £4,971 in dividends, taking your total to £17,120 — and a 71% rise is starting to look reasonable.

But what if, instead of taking and spending your cash handout each year, you had reinvested it in more Glaxo shares?

Before we look at that, let me mention a thing called pound cost averaging — it’s a fancy term that just means you’ll get more shares for the same money over a period when the price dips and recovers than if it had remained flat.

For Glaxo, what that means is that you’d have added just 24 new shares at the end of 2004 when the price was around 1,440p, but by 2007 when it had dropped to 1,210p you’d have scooped up 40 of them.

A decent result

Anyway, with dividends reinvested, you’d be ending the decade with £18,594 — and an 85.5% gain is really nothing to be sniffed at, especially for a share that has actually lagged the FTSE a little over the period (but with better than average dividend yields).

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What next for the Endeavour Mining share price after a record-breaking set of results?

Since March 2025, Endeavour Mining’s share price has risen 175%. Do the gold miner’s latest results provide any clues as…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

How are Rolls-Royce shares looking in March 2026?

March promises to be an interesting time for Rolls-Royce shares, but should investors be worried or calm about developments?

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

3 these stocks are smashing BAE Systems shares – are they worth considering today? 

Harvey Jones looks at the impact of current events on BAE Systems shares this week, and highlights some FTSE 100…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

At a forward P/E of 17, is Nvidia stock now a screaming buy?

Stephen Wright outlines why Nvidia stock could be better value now than it has been in a long time, despite…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

I asked ChatGPT to name the most undervalued share on the UK stock market. Here’s what it said…

Always on the lookout for value shares to add to his portfolio, James Beard turned to a well-known artificial intelligence…

Read more »

High flying easyJet women bring daughters to work to inspire next generation of women in STEM
Investing Articles

Are easyJet shares easy money at 425p?

While other airline stocks have soared since the pandemic, easyJet shares have remained grounded. Is the share price set for…

Read more »

Portrait of a boy with the map of the world painted on his face.
Investing Articles

1 high-flying investment trust to consider for a Stocks and Shares ISA

Ben McPoland thinks this lesser-known trust is worth exploring for investors wanting geographic diversification inside a Stocks and Shares ISA.

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Up 300% from their pandemic lows, has the easy money been made on Lloyds shares?

Investors who bought Lloyds shares at their Covid lows got 15% of their investment back in dividends last year. But…

Read more »